Announcement • 11h
Sigma Healthcare Abandons Boots Takeover Talks The Australian pharmacy group Sigma Healthcare (Sigma Healthcare Limited (ASX:SIG)) has dropped out of talks for a potential takeover of Boots (Boots UK Limited), a deal that would have valued the British retailer at an estimated $10 billion (£7 billion). Sigma, which was in joint talks with the billionaire Weston family, said it had abandoned its pursuit of Boots after concluding it would not meet its investment objectives. In an update to investors, Sigma said: "Sigma engaged in the Boots sale process given the potentially unique opportunity it presented to accelerate its UK expansion through the market-leading Boots brand and large footprint. However, following its preliminary review the company has concluded that such an acquisition would not currently meet its strategic and capital investment objectives." It added that while the Australian market remained its main focus, it would continue to assess potential acquisitions to expand its presence overseas. Boots and Sigma Healthcare declined to comment. Private equity firm Sycamore Partners (Sycamore Partners Management, L.P.), which owns Boots after buying its parent company Walgreens Boots Alliance last year for $23.7 billion, had reportedly begun discussions with possible buyers before Easter. Sycamore Partners revived expectations of a break-up when it bought Walgreens Boots Alliance last year and carved out Boots as a standalone unit. Jonathan De Mello, of JDM Retail, said: "Clearly Sycamore want to realise what they've got in Boots, and to the extent that the Australians were the only band in town looking at it from a trade or financial buyer perspective - and the two are very different - time will tell. But if there isn't that wider interest, then you do start coming round to an IPO". SIG
Live News • Jun 13
Sigma Healthcare Shares Ease as Investors Weigh Growth Plans and Synergy Targets Sigma Healthcare shares have eased as investors locked in profits, even though the company reported positive half-year financial results.
The company is expanding its Chemist Warehouse network in Australia and overseas, while progressing integration efforts tied to this growing footprint.
Management is targeting sizable annual cost synergies by FY2029 from supply chain optimisation and procurement efficiencies, and current updates indicate these synergy goals are on track.
The tension between a fair-value signal from discounted cash flow work and more cautious signals from metrics like the P/E ratio highlights how split the market currently is on Sigma’s valuation and role in the healthcare supply chain.
If you are assessing the stock, the key variables to watch are execution on integration and supply chain projects, and whether the expected long-term synergies are realised without unexpected cost or timing setbacks. Announcement • Jun 10
Boots Owner Reportedly in Talks on Possible $10 Billion Sale The owner of Boots (Boots UK Limited) is talking to parties including the billionaire Weston family and Australian pharmacy group Sigma Healthcare Limited (ASX:SIG) about a $10 billion sale of the UK health and beauty retail business, according to the Financial Times. Private equity firm Sycamore Partners (Sycamore Partners Management, L.P.), which took control of Boots through the acquisition of parent company Walgreens Boots Alliance Inc. last year, began discussions with potential strategic buyers before Easter, the FT said without naming its sources. Representatives for Boots and Sycamore declined to comment. If a sale takes place, it would mean Sycamore may abandon plans for an initial public offering of Boots in London. 
